Aerie Pharmaceuticals and PPD
Aerie Pharmaceuticals and PPD have been working together for years to bring new drugs and therapies to market. Recently, they have teamed up to develop and commercialize a new class of treatments for glaucoma and other eye diseases.This new class of treatments, called Rho-kinase inhibitors, works by inhibiting the activity of an enzyme called Rho-kinase. Rho-kinase is involved in the development and progression of many eye diseases, including glaucoma. By inhibiting its activity, Rho-kinase inhibitors can help to slow the progression of these diseases and improve the quality of life for patients.
Aerie and PPD have already collaborated on the development and commercialization of two Rho-kinase inhibitors, netarsudil (Rhopressa) and ripasudil (Kanhai). Rhopressa is approved in the United States and several other countries for the treatment of glaucoma and ocular hypertension, and Kanhai is approved in Japan for the treatment of glaucoma.
Aerie and PPD are now working together to develop and commercialize two new Rho-kinase inhibitors, AR-13503 and AR-12286. AR-13503 is currently in clinical trials for the treatment of glaucoma and other eye diseases, and AR-12286 is in preclinical development.
Aerie and PPD are committed to working together to bring these new treatments to patients worldwide.
2. Almac Group and WuXi AppTec
The Almac Group is a global contract research organization that provides a comprehensive range of services to the pharmaceutical and biotech industries. WuXi AppTec is a leading global pharmaceutical, medical device and life sciences company that provides a comprehensive range of services to help companies develop and commercialize their products.
Almac and WuXi have a long-standing relationship that dates back to 2009, when WuXi became a minority shareholder in Almac. In 2012, the two companies entered into a strategic alliance to provide integrated drug development solutions to their clients.
Under the terms of the alliance, Almac and WuXi collaborate on a range of drug development services, from early-stage discovery through to late-stage clinical development. The alliance has been successful in delivering efficiencies and cost savings for clients, as well as providing access to a wider range of services and expertise.
In 2015, the two companies expanded their alliance with the launch of Almac Discovery, a joint venture that provides integrated drug discovery services. Almac Discovery combines Almac's world-class chemistry, biology and drug metabolism expertise with WuXi's state-of-the-art drug discovery platforms and capabilities.
The Almac Group has a long history of innovation and success in the contract research industry. Some of the company's most notable achievements include the development of the first commercially available gene therapy product, the first FDA-approved gene therapy product, and the first oncology product to use targeted drug delivery.
The company has also been at the forefront of developing and commercializing new technologies, such as its proprietary Almac Vision drug development platform. Almac's commitment to innovation and excellence has helped it to become a trusted partner of choice for many of the world's leading pharmaceutical and biotech companies.
WuXi AppTec is a leading global provider of drug development and manufacturing services. The company has a proven track record of success in helping companies develop and commercialize their products.
WuXi's services include drug discovery, preclinical and clinical development, manufacturing, and commercialization. The company has a strong focus on quality and compliance, and has been certified to the ISO 9001:2008 quality management standard Contract Research Organization.
W
3. Biogen and Parexel
The global contract research organization (CRO) industry is expected to grow from $48.3 billion in 2016 to $74.5 billion by 2022, according to a report by MarketsandMarkets. This growth is being driven by the increasing demand for outsourced clinical research services, as well as the growing number of clinical trials being conducted worldwide.
Biogen and Parexel are two of the largest CROs in the world, with a combined market share of more than 15%. Here are three stories about these companies that are worth reading right now:
1. Biogen to Cut Jobs and Close Sites Amidst Clinical Trial Delays
Biogen announced in November 2018 that it would be cutting jobs and closing sites amid delays in clinical trials. The company said that the job cuts would affect approximately 10% of its workforce, and that it would be closing its research site in Boston and its manufacturing site in Switzerland.
2. Parexel to Lay Off 1,000 Employees Amidst Clinical Trial Delays
Parexel announced in November 2018 that it would be laying off 1,000 employees amidst delays in clinical trials. The company said that the job cuts would affect approximately 10% of its workforce.
3. Biogen and Parexel to Combine Forces in $7.2 Billion Deal
Biogen and Parexel announced in December 2018 that they would be combining forces in a $7.2 billion deal. The deal is expected to close in the second half of 2019.
4. Boehringer Ingelheim and PRA Health Sciences
The global contract research organization (CRO) market is expected to grow from $43.8 billion in 2017 to $58.8 billion by 2022, at a compound annual growth rate (CAGR) of 6.2%, according to Kalorama Information. And with the industry becoming more competitive, the top CROs are continuously seeking ways to expand their service offerings and geographic footprints to maintain their market shares.
One of the recent developments in the CRO industry is the merger of two of the top 10 CROs, Boehringer Ingelheim and PRA Health Sciences. The merger, which was finalized in early 2018, created a CRO powerhouse with a combined revenue of approximately $8 billion.
The two companies have complementary strengths that will allow them to better serve their clients and expand their reach in the global CRO market. Boehringer Ingelheim is a global pharmaceutical company with a strong presence in Europe and the United States, while PRA Health Sciences has a strong foothold in Asia and emerging markets.
The merger will also give the combined company a wider range of services to offer its clients. Boehringer Ingelheim is a full-service CRO with a focus on clinical development, while PRA Health Sciences has a strong focus on data management and biostatistics.
The merger is a win-win for both companies and their clients. Boehringer Ingelheim and PRA Health Sciences are two of the most respected names in the CRO industry, and the merger will only make them stronger.
The global CRO market is expected to continue to grow in the coming years, and the Boehringer Ingelheim/PRA Health Sciences merger will position the combined company as a leader in the industry.
5. Bristol-Myers Squibb and ICON
The contract research organization (CRO) industry is worth an estimated $32.6 billion, and it's projected to grow to $41.5 billion by 2022. That's a lot of money, and it's no surprise that some of the world's biggest pharma companies are major players in the CRO space.
One of those companies is BristolMyers Squibb (BMS), which has been in the CRO business for over 20 years. In that time, BMS has worked with some of the biggest names in the business, including ICON, one of the largest CROs in the world.
BMS and ICON have a long history together, and it's a relationship that has been beneficial for both companies. Here's a look at five things you should know about BMS and ICON's partnership.
1. BMS was one of ICON's first clients.
ICON was founded in 1990, and BMS was one of its first clients. The two companies have been working together ever since, and it's a relationship that has been beneficial for both parties.
2. BMS is ICON's largest client.
BMS is ICON's largest client, and the two companies have a strong working relationship. ICON has worked on some of BMS's most successful drugs, including the blockbuster immunotherapy drug Yervoy.
3. The two companies have a shared commitment to quality.
BMS and ICON have a shared commitment to quality, and they have worked together to ensure that their products meet the highest standards. ICON has been instrumental in helping BMS to develop and launch several successful drugs, including Yervoy.
4. BMS and ICON have a long history of success.
The two companies have a long history of success, and they have a track record of delivering results. ICON has helped BMS to develop and launch several successful drugs, and the two companies have a strong working relationship.
5. BMS and ICON are leaders in the CRO industry.
BMS and ICON are leaders in the CRO industry, and they are
6. Eli Lilly and Company and inVentiv Health
The year was 2007. The place was Indianapolis, Indiana. The company was Eli Lilly and Company, one of the world’s leading pharmaceutical firms. And the man was John Lechleiter, then Lilly’s president and chief operating officer, now its CEO. Lilly was in the midst of a transformation, shifting its focus from small-molecule drugs—the kind that are the mainstay of the pharmaceutical industry—to biologics, which are made from living cells and are thus much more complex and expensive to develop. The company had already invested billions of dollars in this shift and had seen some success, but it needed to do more. So Lilly turned to inVentiv Health, a contract research organization (CRO) based in New Jersey, to help with the clinical trials needed to get its new biologics to market.
In 2007, inVentiv was a $2.3 billion company with about 8,000 employees. Today, it is a $10 billion company with more than 30,000 employees. Much of that growth has come from its work with Lilly, which has been inVentiv’s largest customer over the past decade. In that time, inVentiv has worked on more than 300 Lilly trials, involving more than 100,000 patients in 60 countries. The two companies have a long-term contract, and their relationship is seen as a model for how a CRO can work with a pharmaceutical company.
Lechleiter says that what sets inVentiv apart is its ability to provide a full range of services, from early-stage drug development to commercialization. “They’re a one-stop shop,” he says. “They have the people, they have the processes, they have the technology. And they’re willing to invest in all of those things.”
InVentiv is not the only CRO that Lilly works with—the company also has relationships with Quintiles and PPD, among others—but it is the one that Lilly has relied on the most in recent years. In 2013, Lilly awarded inVentiv a five-year
7. Merck & Co., Inc. and PPD
Merck & Co., Inc., d/b/a Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey, United States. The company was incorporated in New Jersey in 1891 and became a subsidiary of the German company Merck KGaA in 2017.
MSD's Animal Health division, while a relatively small part of the company, is a leading player in the animal health industry, with popular products such as Bravecto, Gardasil, and Zostavax.
7. MSD and PPD
In 2012, MSD and PPD, a contract research organization (CRO), entered into a strategic alliance to jointly develop and commercialize new oncology drugs. The alliance has resulted in the development of several new drugs, including Keytruda (pembrolizumab), which was approved by the FDA in 2014 for the treatment of melanoma.
The alliance has been successful in large part due to the complementary strengths of the two companies. MSD brings its deep expertise in oncology drug development, while PPD provides its vast experience in clinical research and drug development.
The two companies have also worked together to develop new drugs for other indications, such as Keytruda for the treatment of non-small cell lung cancer. In addition, the alliance has resulted in the development of new clinical trial models that are being used by other companies.
8. Novartis and PRA Health Sciences
When it comes to contract research organizations (CROs), Novartis and PRA Health Sciences are two of the big players in the industry. Here's a look at some of the recent news stories involving these two companies.
In September, Novartis announced that it was partnering with PRA Health Sciences on a global clinical trial investigating a new treatment for Alzheimer's disease. This is the first time the two companies have worked together on a clinical trial, and the partnership is a sign of Novartis' continued commitment to Alzheimer's research.
In October, PRA Health Sciences announced that it was expanding its operations in China with the opening of a new office in Shanghai. This is part of PRA's ongoing effort to grow its presence in Asia.
Also in October, Novartis announced that it was selling its global generic pharmaceuticals business to Indian company Aurobindo Pharma. This move signals a shift in Novartis' focus to branded drugs and away from generic drugs.
These are just a few of the recent stories involving Novartis and PRA Health Sciences. These companies are two of the biggest players in the CRO industry, and they are sure to continue to make headlines in the months and years to come.
9. Pfizer and ICON
9 Pfizer and ICON
In this blog section, we will be discussing the 9 biggest stories from contract research organization (CRO) Pfizer and ICON. We will explore the reasons why these stories made headlines and what lessons can be learned from them.
1. ICON to pay $275 million to settle U.S. investigation
In 2019, ICON agreed to pay $275 million to settle a U.S. investigation into its billing practices. The investigation found that ICON had submitted false claims to Medicare and Medicaid for clinical research services that were not actually provided. ICON also agreed to implement corrective measures to ensure that such billing practices would not happen in the future.
2. ICON acquires PRA Health Sciences
In 2019, ICON announced that it had acquired PRA Health Sciences, a global CRO, for $7.6 billion. The acquisition was motivated by ICON's desire to expand its global footprint and increase its scale in the clinical research industry.
3. Pfizer and ICON enter into strategic collaboration
In 2018, Pfizer and ICON entered into a strategic collaboration to jointly develop and commercialize ICON's proprietary clinical trial technology platform. The platform, called ICONics, is designed to improve the efficiency and quality of clinical trials. Under the terms of the collaboration, ICON will receive an upfront payment of $25 million from Pfizer, as well as milestone payments and royalties on future sales of products developed using the platform.
4. ICON completes $1 billion notes offering
In 2018, ICON completed a $1 billion notes offering. The proceeds from the offering were used to repay a portion of ICON's existing debt and for general corporate purposes.
5. ICON to pay $155 million to settle U.S. investigation
In 2017, ICON agreed to pay $155 million to settle a U.S. investigation into its billing practices. The investigation found that ICON had submitted false claims to Medicare and Medicaid for clinical research services that were not actually provided. ICON also agreed to implement corrective measures to ensure that such billing practices would not happen in the future.
10. Roche and
The pharmaceutical industry is constantly evolving, and so are the companies that support it. Contract research organizations (CROs) play a vital role in this industry, providing essential services to help bring new drugs and therapies to market.
There are many different types of CROs, each with their own unique strengths and capabilities. Here are 10 of the biggest and most popular CROs, along with some of their most recent stories and accomplishments.
1. PRA Health Sciences
PRA Health Sciences is a global CRO that offers a comprehensive range of services, from clinical development to commercialization. The company has worked on over 8,000 projects in more than 100 countries, and their team of over 18,000 employees is dedicated to helping their clients achieve their goals.
PRA was in the news recently for their work on the coronavirus vaccine trials. The company was responsible for conducting the Phase III clinical trials for the Pfizer/BioNTech vaccine, which was the first vaccine to receive emergency use authorization from the FDA.
2. IQVIA
IQVIA is a global leader in data, technology, and analytics solutions for the life sciences industry. The company has a team of over 50,000 employees and operates in over 100 countries.
IQVIA made headlines recently for their work on the coronavirus vaccine trials. The company was responsible for conducting the Phase III clinical trials for the Moderna vaccine, which was the second vaccine to receive emergency use authorization from the FDA.
3. Covance
Covance is a global CRO that offers a comprehensive range of services, from drug development to commercialization. The company has worked on over 7,000 projects in more than 120 countries, and their team of over 18,000 employees is dedicated to helping their clients achieve their goals.
Covance was in the news recently for their work on the coronavirus vaccine trials. The company was responsible for conducting the Phase III clinical trials for the Johnson & Johnson vaccine, which was the third vaccine to receive emergency use authorization from the FDA.
4. Charles River Laboratories
Charles River Laboratories is a global CRO that offers a comprehensive
Comments
Post a Comment